MS medications -- will we ever get the answers to our questions? Maybe we are getting closer.....

Advera Health Analytics, ("evidence based data, analytics, and insights for healthcare decision makers"), recently issued their 2016 Update "Comparative Safety of Multiple Sclerosis Medications." http://rxview.adverahealth.com/the-comparative-safety-of-multiple-sclerosis-medications-a-2016-update?utm_source=hs_email&utm_medium=email&utm_content=29333808&_hsenc=p2ANqtz-8Sl7fvphQ5JLfaQN9FHeOTPKSf6bn_dn_S9XTqOttPxLshhwTE8Dcflq59HFI9wi6_CYC4wGZnuFgpeAH6Ptq0UJ-QpCgMe-PWsLPuTFWodezJj2w&_hsmi=29333808

If looking at study and trial data is something that interests you, then I suggest you subscribe to their blog. "If you subscribe to our monthly RxView Newsletter, then you probably saw the announcement that later in May, annotated data from curated clinical trial results for Multiple Sclerosis (MS) medications will be available in Evidex. Our coverage will include all approved drugs, as well as those in phase II development and above."

and, thanks to Joan Beal for continuing to educate the patient community!

Here is her recent blog: "Ocrelizumab and "wrapping up MS" in her latest blog post
http://ccsviinms.blogspot.com/2016/05/ocrelizumab-and-wrapping-up-ms.html?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+MultipleSclerosis--theVascularConnection+%28Multiple+Sclerosis--the+vascular+connection%29

To set the stage for the launch of our MS Clinical Evidence coverage, I'll provide an update to some of the key tables that were in our June 2014 report.